Milestone Pharmaceuticals To Present Data On Etripamil At The American College Of Cardiology And European Heart Rhythm Association Annual Conferences
Milestone Pharmaceuticals To Present Data On Etripamil At The American College Of Cardiology And European Heart Rhythm Association Annual Conferences
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at two upcoming cardiology conferences this month. The company will deliver oral and poster presentations at the American College of Cardiology annual meeting (ACC24), to be held April 6-8th in Atlanta, Georgia, and a poster presentation at the annual meeting of the European Heart Rhythm Association (EHRA), to be held April 7-9th in Berlin, Germany. The presentations will be available following the embargo at
专注于创新心血管药物开发和商业化的生物制药公司Milestone Pharmicals Inc.（纳斯达克股票代码：MIST）今天宣布，它将在本月即将举行的两次心脏病学会议上公布有关依曲帕米的数据。该公司将在4月6日至8日在佐治亚州亚特兰大举行的美国心脏病学会年会（ACC24）上发表口头和海报演讲，并在4月7日至9日在德国柏林举行的欧洲心律协会（EHRA）年会上发表海报演讲。禁运结束后，演示文稿将在以下网址公布
|
ACC Presentation Details: | ||
| Oral Presentation Title: | Multi-Center, Open-Label Study of the Efficacy and Safety of Etripamil Nasal Spray Self-Administered For Multiple Episodes of Symptomatic Supraventricular Tachycardia Without Supervision (Phase 3, NODE-303) | |
| Presenter: | James Ip, M.D., Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital | |
| Date and time: | Monday, April 8, 2024, 11:36 – 11:46 a.m. EDT | |
| Poster Presentation Title: | Symptom-prompted, Self-administered Intranasal Etripamil for Termination of Paroxysmal Supraventricular Tachycardia in the RAPID Study: Relationship Among Etripamil-Induced Reduction in Tachycardia Rates, Conversion to Sinus Rhythm, and Improvement in Patient Symptoms | |
| Presenter: | James Ip, M.D., Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital | |
| Date and time: | Sunday, April 7, 2024, 12:15 – 1:00 p.m. EDT | |
| EHRA Presentation Details: | ||
| Poster Presentation Title: | Characterising paroxysmal supraventricular tachycardia episodes by patient-perceived episode duration, symptoms, and severity: longitudinal patient-reported outcomes | |
| Presenter: | David Bharucha, M.D., Ph.D., FACC, Chief Medical Officer of Milestone Pharmaceuticals, Inc. | |
| Date and time: | Sunday, April 7, 2024, 10:15 a.m. CET | |
| ACC 演示详情： | ||
| 口头陈述标题： | 多中心、开放标签的研究，探讨在没有监督的情况下自行给药治疗多发有症状的室上性心动过速的Etripamil鼻腔喷雾剂的疗效和安全性（第三阶段，NODE-303） | |
| 演示者： | James Ip，医学博士，纽约长老会医院威尔康奈尔医学院心脏病学部心脏起搏和植入设备教授兼主任 | |
| 日期和时间： | 美国东部时间 2024 年 4 月 8 日星期一上午 11:36 — 11:46 | |
| 海报演示文稿标题： | 在RAPID研究中，以症状提示、自行给药的鼻内注射埃曲帕米用于终止阵发性室上性心动过速：依曲帕米尔诱导的心动过速率降低、转化为鼻窦心律和患者症状改善之间的关系 | |
| 演示者： | James Ip，医学博士，纽约长老会医院威尔康奈尔医学院心脏病学部心脏起搏和植入设备教授兼主任 | |
| 日期和时间： | 美国东部时间 2024 年 4 月 7 日星期日下午 12:15 — 1:00 | |
| EHRA 演示详情： | ||
| 海报演示文稿标题： | 通过患者感知的发作持续时间、症状和严重程度来描述阵发性室上性心动过速发作：患者报告的纵向结果 | |
| 演示者： | 大卫·巴鲁查，医学博士，FACC，Milestone Pharmicals, Inc.首席医学官 | |
| 日期和时间： | 欧洲中部时间 2024 年 4 月 7 日星期日上午 10:15 | |